Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
<p><strong>Aim:</strong> Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. </p> <p><strong>Patients & methods:</strong> Longitudinal QoL was assessed using...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Future Medicine
2020
|
| _version_ | 1797068980330954752 |
|---|---|
| author | Ponce Aix, S Talbot, D Ramaswamy, G Cobo, M Postmus, PE Lewanski, C Bennouna, J Fischer, JR Juan-Vidal, O Stewart, DJ Ardizzoni, A Bhore, R Wolfsteiner, M Reck, M Jin Ong, T Morgensztern, D |
| author_facet | Ponce Aix, S Talbot, D Ramaswamy, G Cobo, M Postmus, PE Lewanski, C Bennouna, J Fischer, JR Juan-Vidal, O Stewart, DJ Ardizzoni, A Bhore, R Wolfsteiner, M Reck, M Jin Ong, T Morgensztern, D |
| author_sort | Ponce Aix, S |
| collection | OXFORD |
| description | <p><strong>Aim:</strong> Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. </p>
<p><strong>Patients & methods:</strong> Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. </p>
<p><strong>Results:</strong> QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19–56% and 9–51% of patients, respectively. </p>
<p><strong>Conclusion:</strong> While QoL trends were promising, additional data are required to support these regimens in this setting.</p> |
| first_indexed | 2024-03-06T22:17:50Z |
| format | Journal article |
| id | oxford-uuid:5404295b-fe48-49eb-8138-1923108b9ac3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:17:50Z |
| publishDate | 2020 |
| publisher | Future Medicine |
| record_format | dspace |
| spelling | oxford-uuid:5404295b-fe48-49eb-8138-1923108b9ac32022-03-26T16:35:09ZQuality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5404295b-fe48-49eb-8138-1923108b9ac3EnglishSymplectic ElementsFuture Medicine2020Ponce Aix, STalbot, DRamaswamy, GCobo, MPostmus, PELewanski, CBennouna, JFischer, JRJuan-Vidal, OStewart, DJArdizzoni, ABhore, RWolfsteiner, MReck, MJin Ong, TMorgensztern, D<p><strong>Aim:</strong> Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. </p> <p><strong>Patients & methods:</strong> Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. </p> <p><strong>Results:</strong> QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19–56% and 9–51% of patients, respectively. </p> <p><strong>Conclusion:</strong> While QoL trends were promising, additional data are required to support these regimens in this setting.</p> |
| spellingShingle | Ponce Aix, S Talbot, D Ramaswamy, G Cobo, M Postmus, PE Lewanski, C Bennouna, J Fischer, JR Juan-Vidal, O Stewart, DJ Ardizzoni, A Bhore, R Wolfsteiner, M Reck, M Jin Ong, T Morgensztern, D Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer |
| title | Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer |
| title_full | Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer |
| title_fullStr | Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer |
| title_full_unstemmed | Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer |
| title_short | Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer |
| title_sort | quality of life with second or third line nab paclitaxel based regimens in advanced non small cell lung cancer |
| work_keys_str_mv | AT ponceaixs qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT talbotd qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT ramaswamyg qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT cobom qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT postmuspe qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT lewanskic qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT bennounaj qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT fischerjr qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT juanvidalo qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT stewartdj qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT ardizzonia qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT bhorer qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT wolfsteinerm qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT reckm qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT jinongt qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer AT morgenszternd qualityoflifewithsecondorthirdlinenabpaclitaxelbasedregimensinadvancednonsmallcelllungcancer |